To include your compound in the COVID-19 Resource Center, submit it here.

Regeneron’s commercial future

Regeneron’s choices for commercializing its pipeline as its Sanofi deal winds down

As its long-standing tie-up with Sanofi winds down, the main loss Regeneron faces is access to the pharma’s commercial footprint, as the biotech has yet to build one for itself.

An analysis of Regeneron’s wholly owned pipeline suggests it may be able to go it alone for about a third, while the others will likely require a partner, particularly outside the U.S.

First partnered in 2003, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN;

Read the full 726 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers